CRK Earnings

CRK reported its FY2025Q4 earnings on 2026-02-11, showcasing a revenue of 0.00 against an estimate of 443.00M, resulting in a 0% surprise. The EPS was 0, surpassing the expected 0.09 by 0% . The stock experienced a 0% price change on the earnings day and a 0% change over the next five days, reflecting market reactions to the results.

Following CRK's FY2025Q4 earnings announcement on 2026-02-11, the stock price moved by % on the day of the release. Over the subsequent five days, it saw a % change. Historically, CRK's stock price tends to shift by an average of +1.66% in the 10 days leading up to earnings and +6.63% in the 10 days following, providing insight into potential market.

For 2025/Q4, analysts estimate CRK’s annual revenue to reach 510.00M, while the EPS is projected at 0.00. These estimates reflect recent revisions, with revenue estimates revised Revenue No Change by 0% and EPS estimates Revise Upward by 28.68% over the past three months, indicating analyst expectation in the company’s performance.

The correlation between CRK's stock price and earnings forecast revisions shows that positive revisions in revenue or EPS often strengthen the stock’s fundamentals. Over the past three months, revenue estimates for FY2025 were No Change by 0%, while EPS estimates moved Revise Upward by 28.68% . This trend suggests that price dips could present buying opportunities for investors.

Based on historical trends, CRK's stock price typically moves by +1.66% in the 10 days before its earnings and +6.63% in the 10 days after. For the upcoming 2025/Q4 earnings, analysts expect an EPS of 0.00 and revenue of 510.00M.

The company's earnings call reveals strong developments in Western and Legacy Haynesville, positive asset divestiture impacts, and robust financial liquidity. Analysts' questions highlight optimism in gas demand and industrial contracts. Despite some unclear responses, the overall sentiment is positive, with strategic expansions and cost efficiencies. Given the market cap, the stock is likely to see a positive reaction in the short term, estimated between 2% to 8%.